HotSpot Therapeutics Collaboration Agreement with Caris Life Sciences

January 10, 2022Client News

Gunderson Dettmer represented client HotSpot Therapeutics Inc., a biotechnology company, in a strategic collaboration agreement with Caris Life Sciences®, a molecular science and technology company. The new partnership enables HotSpot Therapeutics to leverage AI-driven data-mining and interrogation to advance efforts in developing precision medicine.

In the announcement of the transaction, co-founder and CEO of HotSpot Therapeutics Jonathan Montagu said, “HotSpot's Smart Allostery™ drug discovery platform is built on AI-enabled technologies unlocking a cutting-edge pipeline of small molecules designed against difficult-to-drug or yet to be drugged targets in cancer and autoimmune disease. Access to Caris' comprehensive suite of tissue and liquid profiling, real-world data, and broader capabilities will enable robust interrogation of large datasets to accelerate our drug development efforts. This collaboration will yield data-informed insights to inform and speed clinical development and rapidly deliver new treatment options to patients."

The Gunderson deal team was led by Tim Ehrlich and included Joel Diamond.

HotSpot Therapeutics 
Caris Life Sciences®